Literature DB >> 25541438

HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer.

Jae Young So1, Joseph Wahler1, Soumyasri Das Gupta1, David M Salerno1, Hubert Maehr1, Milan Uskokovic1, Nanjoo Suh2.   

Abstract

Tumor-initiating cells (also known as cancer stem cells) are the subpopulation of cells shown to be responsible for tumor initiation, maintenance and recurrence. In breast cancer, CD44(+)/CD24(-/low) cells were identified as tumor-initiating cells. We previously reported that a Gemini vitamin D analog, 1,25-dihydroxy-20R-21(3-hydroxy-3-deuteromethyl-4,4,4-trideuterobutyl)-23-yne-26,27-hexafluoro-cholecalciferol (BXL0124), reduced CD44(+)/CD24(-/low) cells in MCF10DCIS basal-like breast cancer cells. Since Notch has been identified as one of the key signaling pathways involved in breast cancer stem cells, the effect of BXL0124 on the Notch signaling pathway was investigated in breast cancer. The CD44(+)/CD24(-/low) subpopulation of MCF10DCIS cells showed elevated Notch1 signaling and increased cell proliferation compared to the CD44(+)/CD24(high) subpopulation. Treatment with the Gemini vitamin D analog BXL0124 decreased the level of activated Notch1 receptor. In addition, mRNA and protein levels of the Notch ligands, Jagged-1, Jagged-2 and DLL1, were significantly reduced by treatment with BXL0124, which was followed by repression of c-Myc, a key downstream target of Notch signaling. Interestingly, HES1, a known downstream target of Notch signaling, was rapidly induced by treatment with BXL0124. The inhibitory effect of BXL0124 on Notch signaling was reversed by knockdown of HES1. Overexpression of HES1 inhibited Notch1 signaling and reduced the CD44(+)/CD24(-/low) subpopulation, confirming a role of HES1 in Notch1 signaling. In conclusion, the Gemini vitamin D analog, BXL0124, represses the tumor-initiating subpopulation by HES1-mediated inhibition of Notch1 signaling. The present study demonstrates BXL0124 as a potent inhibitor of Notch signaling to target tumor-initiating cells in basal-like breast cancer. This article is part of a Special Issue entitled "17th Vitamin D Workshop".
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; CD44(+)/CD24(-/low) cells; Gemini vitamin D analog; HES1; Notch signaling; Tumor-initiating cells

Mesh:

Substances:

Year:  2014        PMID: 25541438      PMCID: PMC4361253          DOI: 10.1016/j.jsbmb.2014.12.013

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  55 in total

Review 1.  Targeting Notch to target cancer stem cells.

Authors:  Antonio Pannuti; Kimberly Foreman; Paola Rizzo; Clodia Osipo; Todd Golde; Barbara Osborne; Lucio Miele
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

2.  Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer.

Authors:  Patricia M McGowan; Carmen Simedrea; Emeline J Ribot; Paula J Foster; Diane Palmieri; Patricia S Steeg; Alison L Allan; Ann F Chambers
Journal:  Mol Cancer Res       Date:  2011-06-10       Impact factor: 5.852

Review 3.  Targeted therapies for breast cancer.

Authors:  Michaela J Higgins; José Baselga
Journal:  J Clin Invest       Date:  2011-10-03       Impact factor: 14.808

4.  The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance.

Authors:  Karisa C Schreck; Pete Taylor; Luigi Marchionni; Vidya Gopalakrishnan; Eli E Bar; Nicholas Gaiano; Charles G Eberhart
Journal:  Clin Cancer Res       Date:  2010-12-15       Impact factor: 12.531

5.  A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer.

Authors:  Jae Young So; Hong Jin Lee; Amanda K Smolarek; Shiby Paul; Chung-Xiou Wang; Hubert Maehr; Milan Uskokovic; Xi Zheng; Allan H Conney; Li Cai; Fang Liu; Nanjoo Suh
Journal:  Mol Pharmacol       Date:  2010-11-29       Impact factor: 4.436

Review 6.  The cancer stem cell: premises, promises and challenges.

Authors:  Hans Clevers
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

7.  Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling.

Authors:  Hong Jin Lee; Jae-Young So; Andrew DeCastro; Amanda Smolarek; Shiby Paul; Hubert Maehr; Milan Uskokovic; Nanjoo Suh
Journal:  J Steroid Biochem Mol Biol       Date:  2010-03-19       Impact factor: 4.292

8.  JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer.

Authors:  Michael Reedijk; Dushanthi Pinnaduwage; Brendan C Dickson; Anna Marie Mulligan; Hui Zhang; Shelley B Bull; Frances P O'Malley; Sean E Egan; Irene L Andrulis
Journal:  Breast Cancer Res Treat       Date:  2007-11-08       Impact factor: 4.872

9.  Hes1 regulates embryonic stem cell differentiation by suppressing Notch signaling.

Authors:  Taeko Kobayashi; Ryoichiro Kageyama
Journal:  Genes Cells       Date:  2010-06-10       Impact factor: 1.891

10.  Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines.

Authors:  Matthew J Meyer; Jodie M Fleming; Mustapha A Ali; Mitchell W Pesesky; Erika Ginsburg; Barbara K Vonderhaar
Journal:  Breast Cancer Res       Date:  2009-11-11       Impact factor: 6.466

View more
  19 in total

Review 1.  FXR1a-associated microRNP: A driver of specialized non-canonical translation in quiescent conditions.

Authors:  Syed I A Bukhari; Shobha Vasudevan
Journal:  RNA Biol       Date:  2016-12-02       Impact factor: 4.652

2.  Tocopherols inhibit estrogen-induced cancer stemness and OCT4 signaling in breast cancer.

Authors:  Min Ji Bak; Philip Furmanski; Naing Lin Shan; Hong Jin Lee; Cheng Bao; Yong Lin; Weichung Joe Shih; Chung S Yang; Nanjoo Suh
Journal:  Carcinogenesis       Date:  2018-07-30       Impact factor: 4.944

Review 3.  Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects.

Authors:  Sylvia Christakos; Puneet Dhawan; Annemieke Verstuyf; Lieve Verlinden; Geert Carmeliet
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

Review 4.  Breast Cancer Metastasis: Mechanisms and Therapeutic Implications.

Authors:  Misung Park; Dohee Kim; Sunghyub Ko; Ayoung Kim; Kyumin Mo; Hyunho Yoon
Journal:  Int J Mol Sci       Date:  2022-06-18       Impact factor: 6.208

5.  Delta/notch-like epidermal growth factor-related receptor (DNER) orchestrates stemness and cancer progression in prostate cancer.

Authors:  Lijun Wang; Qi Wu; Shan Zhu; Zhiyu Li; Jingping Yuan; Dehua Yu; Zhiliang Xu; Juanjuan Li; Shengrong Sun; Changhua Wang
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

6.  Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma In Situ by Vitamin D Compounds.

Authors:  Naing Lin Shan; Audrey Minden; Philip Furmanski; Min Ji Bak; Li Cai; Roman Wernyj; Davit Sargsyan; David Cheng; Renyi Wu; Hsiao-Chen D Kuo; Shanyi N Li; Mingzhu Fang; Hubert Maehr; Ah-Ng Kong; Nanjoo Suh
Journal:  Cancer Prev Res (Phila)       Date:  2020-05-28

7.  Structural analysis and biological activities of BXL0124, a gemini analog of vitamin D.

Authors:  Anna Y Belorusova; Nanjoo Suh; Hong Jin Lee; Jae Young So; Hubert Maehr; Natacha Rochel
Journal:  J Steroid Biochem Mol Biol       Date:  2016-09-17       Impact factor: 4.292

Review 8.  Emerging role of tumor cell plasticity in modifying therapeutic response.

Authors:  Siyuan Qin; Jingwen Jiang; Yi Lu; Edouard C Nice; Canhua Huang; Jian Zhang; Weifeng He
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

9.  Lunatic Fringe and p53 Cooperatively Suppress Mesenchymal Stem-Like Breast Cancer.

Authors:  Wen-Cheng Chung; Shubing Zhang; Lavanya Challagundla; Yunyun Zhou; Keli Xu
Journal:  Neoplasia       Date:  2017-09-19       Impact factor: 5.715

10.  Common profiles of Notch signaling differentiate disease-free survival in luminal type A and triple negative breast cancer.

Authors:  Magdalena Orzechowska; Dorota Jędroszka; Andrzej K Bednarek
Journal:  Oncotarget       Date:  2017-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.